The Relation between D-Dimer, Hs-CRP, and ACE Inhibitor to Severity, Reinfection, and Mortality of COVID-19 Patients
DOI:
https://doi.org/10.36497/jri.v44i4.465Keywords:
ACE, COVID-19, D-Dimer, Hs-CRP, inhibitor, reinfectionAbstract
Background: COVID-19 reinfection has been found, although the data is not clear yet. Pandemic conditions bring about limited facilities and infrastructure, so biomarkers are an option. Research on biomarkers and the use of ACE inhibitor drugs in COVID-19 patients has not been widely conducted in Indonesia.
Methods: This was a retrospective cohort study that used medical record data of confirmed COVID-19 patients treated at dr. Moewardi General Hospital for the period of January to March 2022. Surviving patients were observed for reinfections until November 2022.
Results: This study involved 524 medical records of confirmed COVID-19 patients. After exclusion and inclusion criteria, 517 medical records were obtained. D-Dimer cut-off values of ≥2435 were significantly related to severity (OR=2.05; 95% CI=1.38-3.06; P≤0.001) and mortality (OR=2.89; 95% CI=1.95-4.27; P≤0.001) of COVID-19 patients. Hs-CRP levels ≥4.59 were significantly associated with mortality in COVID-19 patients (OR=1.82; 95% CI=1.23-2.69; P=0.003). The use of ACE inhibitors (OR=0.55; 95% CI=0.33-0.89; P=0.015) was a protective factor from mortality but increased the risk of reinfection (OR=3.11; 95% CI=1.16-8.36; P=0.034).
Conclusion: D-Dimer and Hs-CRP biomarkers could be considered as predictor biomarkers for the severity and mortality of COVID-19 patients. Although the use of ACE inhibitors increased the risk of reinfection, it reduced the risk of mortality due to COVID-19.
Downloads
References
Burhan E, Isbaniah F, Susanto AD, Yoga T, Aditama, Soedarsono, et al. Manifestasi klinis. In: Pneumonia COVID-19 diagnosis dan penatalaksanaan di Indonesia. 1st ed. 2015.
World Health Organization. World health statistics 2022: Monitoring health for the SDGs, sustainable development goals. 2022.
Satuan Tugas Penanganan COVID-19. Analisis Data COVID-19 Indonesia (Update Per 21 Agustus 2022) [Internet]. Satuan Tugas Penanganan COVID-19. 2022 [cited 2022 Aug 21]. Available from: https://covid19.go.id/p/berita/analisis-data-covid-19-indonesia-update-28-februari-2021
Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: A systematic review and meta-analysis. Sci Rep. 2020;10(1):20692.
Ozaras R, Ozdogru I, Yilmaz AA. Coronavirus disease 2019 re-infection: First report from Turkey. New Microbes New Infect. 2020;38:100774.
Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83.
Adrielle dos Santos L, Filho PG de G, Silva AMF, Santos JVG, Santos DS, Aquino MM, et al. Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. Journal of Infection. 2021;82(3):399–406.
Qureshi AI, Baskett WI, Huang W, Lobanova I, Hasan Naqvi S, Shyu CR. Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients undergoing serial laboratory testing. Clinical Infectious Diseases. 2022;74(2):294–300.
Islam MdZ, Riaz BK, Akbar Ashrafi SA, Farjana S, Efa SS, Khan MA. Severity of COVID-19 reinfection and associated risk factors: Findings of A cross-sectional study in Bangladesh. medRxiv. 2022;1.
Amirfakhryan H, safari F. Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. Hellenic Journal of Cardiology. 2021;62(1):13–23.
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. Aging. 2020;12(7):6049–57.
Petrovic V, Radenkovic D, Radenkovic G, Djordjevic V, Banach M. Pathophysiology of cardiovascular complications in COVID-19. Front Physiol. 2020;11:575600.
Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri NA, Lihawa N. Comorbidities and mortality in COVID-19 patients. Gac Sanit. 2021;35 Suppl 2:S530–2.
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389–99.
Peiró ÓM, Carrasquer A, Sánchez-Gimenez R, Lal-Trehan N, del-Moral-Ronda V, Bonet G, et al. Biomarkers and short-term prognosis in COVID-19. Biomarkers. 2021;26(2):119–26.
Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.
Bwire GM. Coronavirus: Why men are more vulnerable to Covid-19 than women? SN Compr Clin Med. 2020;2(7):874–6.
Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, Ikatan Dokter Anak Indonesia. Pedoman tatalaksana COVID-19. 4th ed. Burhan E, Susanto AD, Isbaniah F, Nasution SA, Ginanjar E, Pitoyo CW, et al., editors. Pedoman tatalaksana COVID-19 edisi 4. Indonesia; 2022.
Lau ES, McNeill JN, Paniagua SM, Liu EE, Wang JK, Bassett I V., et al. Sex differences in inflammatory markers in patients hospitalized with COVID-19 infection: Insights from the MGH COVID-19 patient registry. PLoS One. 2021;16(4):e0250774.
Al-Kuwari MG, AbdulMalik MA, Al-Nuaimi AA, Abdulmajeed J, Al-Romaihi HE, Semaan S, et al. Epidemiology characteristics of COVID-19 infection amongst primary health care workers in Qatar: March-October 2020. Front Public Health. 2021;9:679254.
Fathi M, Vakili K, Sayehmiri F, Mohamadkhani A, Hajiesmaeili M, Rezaei-Tavirani M, et al. The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS One. 2021;16(2):e0246190.
Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and older adults: What we know. J Am Geriatr Soc. 2020;68(5):926–9.
Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–87.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–74.
Norouzi M, Norouzi S, Ruggiero A, Khan MS, Myers S, Kavanagh K, et al. Type-2 diabetes as a risk factor for severe covid-19 infection. Microorganisms. 2021;9(6):1211.
Abbasi J. Study suggests lasting immunity after COVID-19, with a big boost from vaccination. JAMA - Journal of the American Medical Association. 2021;326(5):376–7.
Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science (1979). 2021;372(6549):1413–8.
Burtis CA, Bruns DE. Cardiovascular disease. In: Tietz - Fundamentos de Química Clínica e Diagnóstico Molecular. 7th ed. Missouri: Elsevier Inc.; 2015. p. 1560–99.
Liu Z, Wu D, Han X, Jiang W, Qiu L, Tang R, et al. HsCRP variation is the main risk factor for clinical outcome in COVID-19 hospitalized young and middle-aged patients. Res Sq. 2020;7:1–19.
Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. JCI Insight. 2021;6(13):e148980.
He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11(1):1830.
Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. American Journal of Emergency Medicine. 2021;39:173–9.
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Diagnosis kasus cardiovascular pada pasien COVID-19. In: Firdaus I, Sukmawan R, Santoso A, Juzar DA, editors. Panduan diagnosis dan tatalaksana penyakit kardiovaskular pada pandemi COVID-19. 1st ed. Jakarta: H&B PERKI; 2020.
Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77–83.
Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, et al. Mortality and severity in COVID-19 patients on ACEIs and ARBs—A systematic review, meta-analysis, and meta-regression analysis. Front Med (Lausanne). 2022;8:703661.
Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ace-inhibitors and arbs in covid-19 patients. Elife. 2020;9:e57278.
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–8.
Sabah Khalid S, Mohamed Ali Z, Faris Raheem M. Serum levels of homocysteine, troponin-I, and high sensitive c-reactive protein in Iraqi COVID-19 patients. Journal of Contemporary Medical Sciences. 2022;8(3):189–93.
El-Shabrawy M, Alsadik ME, El-Shafei M, Abdelmoaty AA, Alazzouni AS, Esawy MM, et al. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. The Egyptian Journal of Bronchology. 2021;15(1):5.
Ahirwar AK, Takhelmayum R, Sakarde A, Rathod BD, Jha PK, Kumawat R, et al. The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: A retrospective study. Horm Mol Biol Clin Investig. 2022;43(3):337–44.
Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–9.
Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (Covid-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219.
South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305–7.
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537–40.
Khan KS, Reed-Embleton H, Lewis J, Bain P, Mahmud S. Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study. Scott Med J. 2020;65(4):149–53.
Baigent C, Windecker S, Andreini D, Arbelo E, Barbato E, Bartorelli AL, et al. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1-epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2022;43(11):1385–412.
Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. Journal of Neuroimmune Pharmacology. 2020;15(3):359–86.
Downloads
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
